Last reviewed: June 10, 2026
Last updated: June 10, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The search for needle-free weight loss options has drawn attention to GLP-1 patches, yet the clinical reality differs from marketing hype. Current injectable GLP-1 medications have demonstrated weight reductions of 15–22% in landmark trials, while patch formulations remain largely experimental. PlexusDx specializes in evidence-based GLP-1 therapy through injections and oral options that have undergone rigorous human testing.
Where GLP-1 Patches Stand in Clinical Development
GLP-1 receptor agonist patches are not yet available as approved medications in the United States. Several pharmaceutical companies have explored transdermal delivery systems to avoid injections, but these formulations have not completed Phase III clinical trials or received FDA clearance. The challenge lies in delivering peptide molecules—which are large and easily broken down by stomach acid—through the skin barrier in sufficient quantities to produce meaningful weight loss.
Early research suggests that microneedled patches and other novel delivery systems could theoretically work, but human efficacy and safety data remain limited. No major regulatory body has approved a GLP-1 patch for weight management to date. This means any product marketed as a functional GLP-1 patch lacks the clinical validation that injectable semaglutide and tirzepatide possess from thousands of trial participants.
Why Injectable GLP-1 Remains the Gold Standard
Injectable GLP-1 medications bypass the digestive system entirely, delivering the active compound directly into subcutaneous tissue where it reaches therapeutic concentrations reliably. The STEP trials (Semaglutide Treatment Effect in People with obesity) showed that weekly semaglutide injections produced average weight loss of 15.3 kg over 68 weeks—approximately 15% of body weight. Tirzepatide, a dual GLP-1 and GIP receptor agonist, demonstrated even greater reductions in the SURMOUNT trials, with participants losing up to 22% of their starting weight.
These results come from randomized controlled trials involving thousands of participants across multiple continents. Injectable formulations offer predictable pharmacokinetics, meaning the dose the body receives is consistent from week to week. PlexusDx sources compounded semaglutide injections from licensed 503A compounding pharmacies, ensuring the same evidence-backed mechanism that powered these clinical successes.
Oral GLP-1: A Proven Alternative to Patches
If needle anxiety drives interest in patches, oral semaglutide and oral tirzepatide offer needle-free options with robust clinical evidence. Oral semaglutide (Rybelsus) achieved approximately 10–13% weight loss in controlled trials, while newer oral tirzepatide formulations are showing comparable or superior results. These tablets work by using permeation enhancers that help peptides survive stomach acid and absorb through the intestinal lining.
PlexusDx offers both Oral Semaglutide (starting at $249/mo) and Oral Tirzepatide (starting at $279/mo) from licensed compounding pharmacies. Oral formulations require careful timing and consistency—typically taken on an empty stomach—but they eliminate the injection step for patients who prefer tablets. Both oral and injectable GLP-1s from PlexusDx are HSA/FSA eligible and available across all 50 states without insurance requirements.
Personalized GLP-1 Selection Through Genetic Testing
Individual responses to GLP-1 therapy vary significantly based on genetic predispositions across multiple peptide pathways. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month of treatment), which maps 14 metabolic pathways and 49 peptides to identify which GLP-1 formulation and companion protocols are most likely to work for your unique biology. The test examines key variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—each influencing appetite regulation, metabolic rate, and medication responsiveness.
This genetic roadmap helps PlexusDx clinicians determine whether semaglutide injection, tirzepatide injection, oral formulations, the Microdose GLP-1 Protocol ($129/mo), or GLP-Squared combinations are most appropriate for your weight loss goals. Precision-matched therapy reduces trial-and-error dosing and increases the likelihood of sustainable results. No patch can offer this level of personalized medicine because patches have not undergone the research needed to understand genetic response patterns.
Safety, Side Effects, and What Evidence Actually Shows
Injectable and oral GLP-1 medications carry well-documented side effect profiles from thousands of clinical trial participants: nausea, vomiting, constipation, and potential pancreatitis risk in susceptible individuals. These risks have been studied extensively, monitored, and are manageable through dose escalation protocols and patient education. Compounded medications from licensed 503A pharmacies must meet the same potency and purity standards as branded pharmaceuticals.
Transdermal patches, by contrast, have not been evaluated in large human safety trials, so the incidence and severity of side effects remain unknown. Choosing an unproven delivery method bypasses years of safety data collected from real patients. PlexusDx offers injectable and oral GLP-1 therapies with transparent, evidence-based risk profiles and clinician oversight to monitor for adverse events throughout treatment.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Are GLP-1 patches FDA-approved for weight loss?
No. As of 2024, no GLP-1 patch has received FDA approval for weight management. Injectable semaglutide and tirzepatide, plus oral formulations, have completed rigorous clinical trials and regulatory review. PlexusDx offers these proven options through licensed 503A compounding pharmacies.
How much weight can I expect to lose with GLP-1 injections?
Clinical trials show average weight loss of 15–22% of starting body weight over 68 weeks, depending on the medication and individual factors. Results vary based on genetics, lifestyle adherence, and baseline metabolism. PlexusDx's Precision Peptide Genetic Test can help predict your likely response.
What is the cost of GLP-1 therapy with PlexusDx?
Compounded Semaglutide Injection starts at $149/mo, Oral Semaglutide at $249/mo, and Tirzepatide options range from $249–$279/mo depending on formulation. Your dose may need to go up. Your price won't. All treatments are available without insurance and are HSA/FSA eligible.
What side effects should I expect from injectable GLP-1?
Common side effects include nausea, vomiting, constipation, and mild diarrhea, especially during dose escalation. Most symptoms resolve as the body adjusts. Serious risks like pancreatitis are rare but require medical monitoring. PlexusDx clinicians provide ongoing oversight and dose management to minimize side effects.
How does the Precision Peptide Genetic Test improve my results?
The test identifies your unique genetic profile across 14 metabolic pathways and 150+ insights related to appetite, fat storage, and medication response. Results guide clinicians to recommend semaglutide, tirzepatide, or combined protocols most likely to succeed for your biology, increasing efficacy and reducing dosing uncertainty.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Unlocking Your Potential: Understanding Who Can Take Semaglutide for Weight Management
How Does GLP-1 Help You Lose Weight?